Immediate Impact
2 from Science/Nature 56 standout
Citing Papers
Epigenetics-targeted drugs: current paradigms and future challenges
2024 Standout
Antibodies to watch in 2024
2024 Standout
Works of Ming‐Chung Wang being referenced
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
2023
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Ming‐Chung Wang | 156 | 117 | 93 | 212 | 190 | 47 | 566 | |
| Colette Chapuis‐Cellier | 152 | 99 | 69 | 110 | 97 | 40 | 588 | |
| Shigehisa Mori | 105 | 79 | 109 | 243 | 238 | 40 | 612 | |
| Ahmad Amanzada | 65 | 37 | 49 | 219 | 142 | 52 | 599 | |
| Chen Cj | 72 | 27 | 21 | 191 | 127 | 43 | 552 | |
| D.A.F. Chamone | 36 | 213 | 32 | 102 | 60 | 43 | 487 | |
| Patricia Baré | 93 | 28 | 50 | 222 | 218 | 44 | 640 | |
| Jian Su | 32 | 131 | 19 | 119 | 74 | 48 | 473 | |
| Alida Harahap | 58 | 116 | 25 | 95 | 56 | 86 | 607 | |
| Kiyoshi Furuta | 74 | 17 | 25 | 227 | 218 | 28 | 462 | |
| Shozo Miyake | 46 | 33 | 21 | 346 | 427 | 37 | 627 |
All Works
Login with ORCID to disown or claim papers
Loading papers...